RecruitingRelapsed/Refractory B-cell Malignancies

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Eligible age

18+ yrs

Accepts

All genders

Locations

3 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.

Sponsor: Ubix Therapeutics, Inc.

Where it's recruiting

Michigan

Ann Arbor

Oklahoma

Canton

Texas

Houston

Source: ClinicalTrials.gov · NCT06590961 · last updated 2025-11-19